

Noxafil[®] (posaconazole) – First-time generic

- On June 29, 2023, [Par](#) launched an [AB-rated](#) generic version of Merck's [Noxafil \(posaconazole\)](#) injection.
- Noxafil injection is approved for treatment of invasive aspergillosis and prophylaxis of invasive *Aspergillus* and *Candida* infections.
 - The generic posaconazole injection is only approved for the prophylaxis of invasive *Aspergillus* and *Candida* infections due to pediatric exclusivity.
- Posaconazole is also available generically as a delayed-release [tablet](#) and oral suspension.
 - The tablet and oral suspension carry the same indications as Noxafil injection. In addition, the oral suspension is approved for the treatment of oropharyngeal candidiasis.
- According to IQVIA[™], Noxafil injection sales were approximately \$25 million for the 12 months ended May 31, 2023.